226. 間質性膀胱炎（ハンナ型） Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
臨床試験数 : 145 / 薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01824303 (ClinicalTrials.gov) | March 2013 | 31/3/2013 | Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis | A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension | Interstitial Cystitis | Drug: LiRIS 400 mg;Other: LiRIS Placebo | Allergan | TARIS Biomedical, Inc. | Terminated | 18 Years | N/A | Female | 31 | Phase 2 | United States;Canada |